

BARBARA WYMAN, <i>et al.</i> ,	)	
	)	2:06-CV-1329-RCJ-GWF
Plaintiffs,	)	
	)	
vs.	)	<b>ORDER</b>
	)	
MERCK & COMPANY, INC., <i>et al.</i> ,	)	
	)	
Defendants.	)	
	)	

## BACKGROUND

Plaintiffs seek to recover damages related to the alleged increase in health risks, including heart attack and stroke, resulting from ingestion of Vioxx, an anti-inflammatory medication manufactured by Defendant Merck & Company, Inc. (“Merck”). Pursuant to the order of the Judicial Panel on Multidistrict Litigation creating MDL No. 1657, Judge Fallon of Eastern District of Louisiana is coordinating hundreds of Vioxx-related actions across the country under 28 U.S.C. § 1407. This case has been conditionally transferred to Judge

1 Fallon's court and Plaintiff's have noticed an opposition. Merck requests a stay in these  
2 proceedings pending the MDL Court's final decision on transfer.

### 3 **DISCUSSION**


4 MDL No. 1657 was created to centralize Vioxx litigation in order to eliminate  
5 duplicative discovery, prevent inconsistent or repetitive rulings, and conserve judicial and  
6 party resources. Despite the presence of the MDL proceeding, Plaintiffs oppose transfer to  
7 the MDL and ask this Court to remand the case to state court. They contend that this action  
8 was improperly removed to federal court by Defendants on the basis of fraudulent joinder of  
9 the Detailer Defendants. Plaintiffs assert that the record clearly shows an absence of  
10 fraudulent joinder, stripping the Court of diversity jurisdiction over the parties. Believing  
11 that jurisdiction is clearly lacking, Plaintiffs move the Court to remand the case to state court  
12 an deny the motion to stay.  
13

14 The Court finds that the remand issues in this case, including fraudulent joinder,  
15 would be best decided by the MDL Court. As Judge Dawson noted in his Order staying a  
16 similar Vioxx case, "The hundreds of Vioxx cases currently pending before MDL No. 1657  
17 present similar factual and legal issues regarding both the effects of Vioxx and remand issues  
18 such as fraudulent joinder. Because MDL 1657 is gaining ample experience examining the  
19 relevant facts for fraudulent joinder analysis, the interests of consistency, economy and  
20 fairness support their addressing the remand issue." *Mangani v. Merck*, 2:06-CV-0914-KJD-  
21 PAL (#20). The Court is persuaded by Judge Dawson's analysis and elects to follow him and  
22 the other Judges in the District of Nevada that have stayed similar Vioxx-related cases in  
23 these circumstances.  
24

**CONCLUSION**

Therefore, IT IS HEREBY ORDERED that Defendant Merck's Motion to Stay (#4) is *granted*. IT IS FURTHER ORDERED that proceedings in this case are STAYED pending a final decision by the MDL Panel regarding possible transfer or ninety (90) days, whichever comes first.

DATED: January 24, 2007.

A handwritten signature in black ink, appearing to read "R. Jones", is written over a horizontal line.

ROBERT C. JONES  
UNITED STATES DISTRICT JUDGE